The startup develops gene editing technology that directs cells to utilize error-free repair pathways, minimizing cellular toxicity while enabling large genomic edits. This approach aims to create genetic cures for liver and pancreatic diseases by addressing the challenges of precise DNA manipulation for therapeutic applications.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of individuals globally are affected by rare genetic diseases, many of which currently lack curative treatments. Traditional gene editing techniques often face challenges in achieving precise DNA manipulation and minimizing cellular toxicity, hindering the development of effective therapies for liver and pancreatic diseases.
Solution
Eucalyptus Bio is developing a gene editing technology focused on directing cells to utilize error-free repair pathways, thereby minimizing cellular toxicity and enabling large genomic edits. Their approach aims to create genetic cures for diseases, particularly those affecting the liver and pancreas, by overcoming the limitations of existing DNA manipulation methods. The core technology facilitates long-range corrective editing, allowing for the rewrite or replacement of multi-kilobase genomic segments. This precision editing aims to address the underlying genetic causes of diseases with greater accuracy and reduced off-target effects.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing genetic cures for rare diseases, particularly those affecting the liver and pancreas.
Features
- Technology enables multi-kilobase long-range genomic rewrite/replace editing.
- Aims to direct cells to utilize error-free repair pathways.
- Designed to minimize cellular toxicity during gene editing.